BioLife Solutions (BLFS +5.2%) initiated at Cowen with Outperform, PT $33, indicating the stock is significantly undervalued; currently hovering around 52-week high levels gained 166% in past 6 months trading.
Wall Street Analysts Rating is Very Bullish, PT $25.36 has been crossed already by the company.
Analyst said that the company is a leading provider of specialized bio-production tools that are critical to cell and gene therapies, an “emerging but rapidly growing class of drugs.”
He further adds that BioLife is a premier emerging growth story in healthcare and should be a core long-term holding.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.